Using Gut Microbial Gbu Gene Testing to Estimate Host TMAO Production Capacity

The risk of developing cardiovascular diseases due to the consumption of red meat varies among individuals, and this may be attributed to differences in the composition and function of gut microbiota. Studies have found that red meat, rich in L-carnitine, may be metabolized by certain anaerobic bacteria in the intestines to produce trimethylamine N-oxide (TMAO) in the human body. Previous research utilizing the oral carnitine challenge test (OCCT) revealed that not everyone experiences a significant increase in blood TMAO levels after consuming carnitine. Moreover, individuals with high TMAO production and low TMAO production showed distinct differences in their gut microbiota.

Furthermore, we have discovered a significant correlation between the abundance of the gbu gene in gut microbiota and the production of TMAO in response to dietary carnitine intake. Therefore, through the design of clinical research, we aim to investigate and assess whether the abundance of the gbu gene in gut microbiota can predict the levels of TMAO produced in the human body under dietary carnitine intake.

Inclusion criteria

• Adult with age between 18 to 70
• Must be able to swallow tablets

Exclusion criteria

• Antibiotics use within one month
• L-carnitine supplement use within one month
• Chronic diarrhea
• Myasthenia gravis
• Diabetes mellitus
• Parathyroid disorders
• Chronic kidney disease
• Epilepsy
• Severe anemia
• Cardiovascular diseases.